EDUCATIONJune 1, 2026· 10 min read

The Evidence Ladder: How to Tell If a Peptide Claim Is Real or Marketing

Someone on Instagram says BPC-157 “cured” their gut. A clinic website claims peptides will “reverse aging.” A Reddit post says Selank is “better than Xanax.” How do you know what’s real? You climb the evidence ladder.

The Ladder

LEVEL 1
Strongest
Phase 3 RCTs & FDA Approval — Large, randomized, controlled trials with thousands of subjects. Replicated results. FDA review of safety and efficacy.
Peptides here: Semaglutide, Tirzepatide, PT-141 (Vyleesi), Tesamorelin
LEVEL 2
Phase 2 Trials & International Approval — Controlled human studies with hundreds of subjects. Some peptides approved in other countries.
Peptides here: Thymosin Alpha-1 (approved in 35+ countries), Kisspeptin-54 (IVF Phase 2), Retatrutide (Phase 3 in progress)
LEVEL 3
Pilot Studies & Small Human Trials — Small human studies (5-60 subjects). Often uncontrolled or unblinded. Encouraging but not definitive.
Peptides here: BPC-157 (12-woman IC pilot), Selank (Russian clinical studies, 21 patients), DSIP (historical human studies)
LEVEL 4
Extensive Preclinical Research — Hundreds of animal studies with consistent results. Strong mechanistic understanding. No or minimal human data.
Peptides here: BPC-157 (tissue repair), TB-500, KPV (inflammation), MOTS-C (metabolism)
LEVEL 5
Limited Preclinical & Mechanistic — Some animal or cell studies. Plausible mechanism. Very early research.
Peptides here: Epitalon (telomeres), SS-31 (mitochondrial), SNAP-8 (cosmetic)
LEVEL 6
Weakest
Anecdotal & Community Reports — User testimonials, Reddit posts, clinic marketing claims, influencer endorsements. No controlled data.
Claims here: “Cured my [condition],” “Better than any drug,” “Reversed aging,” Before/after photos without context

How to Use the Ladder

When you encounter a peptide claim, ask: Where does this evidence sit on the ladder? Level 1-2 claims can be made with confidence. Level 3-4 claims should use words like “may,” “preliminary evidence suggests,” and “animal studies show.” Level 5-6 claims should be treated as hypotheses, not facts.

The FemPeptides standard: Every article on this site identifies the evidence level for each peptide claim. We use traffic light indicators: FDA-approved / strong clinical evidence. Preclinical / early clinical evidence. Anecdotal or mechanistic only. We believe women deserve to know the difference between “this is proven” and “this is promising but unproven.”

Red Flags in Peptide Marketing

They say...What it actually means
“Clinically proven”Usually means one small study or preclinical data. Ask: Phase? Sample size? Published where?
“Doctor recommended”A single affiliated doctor recommending their own product is not meaningful endorsement
“100% safe / no side effects”Nothing is 100% safe. This claim itself is a red flag
“Thousands of satisfied customers”Testimonials are Level 6 evidence. Customer satisfaction ≠ clinical efficacy
“Before and after” photosWithout controlled conditions, these prove nothing. Lighting, angle, timing, and selection bias
“Research shows...” (no citation)If they don’t link the actual study, assume it doesn’t say what they claim

Source Quality-Tested Peptides

BioPure Peptides — Code POWER Midwest Peptide — Code POWER Apollo Peptide Sciences Amino Club — Code POWER

Related Articles

Medical Disclaimer: Educational content only. Not medical advice. Affiliate Disclosure: FemPeptides may earn commissions from vendor links. Full disclosure →

Frequently Asked Questions

What is the strongest evidence for any peptide?

Semaglutide and tirzepatide have the strongest evidence — massive Phase 3 RCTs with thousands of participants, FDA approval for multiple indications, and years of post-market safety data. PT-141 (Vyleesi) has strong Phase 3 evidence for HSDD in premenopausal women. Tesamorelin is FDA-approved for visceral fat reduction. These are Level 1 evidence.

Is BPC-157 evidence strong enough to use?

BPC-157 has Level 3-4 evidence: one small human pilot study (12 women with IC) and extensive preclinical data (hundreds of animal studies). The preclinical evidence is remarkably consistent, but the lack of controlled human trials means we can't be certain these results translate. The July 2026 PCAC review may be a step toward generating better human evidence. Reasonable people can disagree on whether current evidence justifies use.

How do I evaluate claims from a peptide clinic?

Apply the ladder. Ask: What specific study are you referencing? Phase number, sample size, publication journal. Is the study in humans or animals? Is the study independent or conducted by the clinic selling the peptide? Does the study specifically address my condition, sex, and age group? If the clinic can't or won't answer these questions, that tells you something.

Why do you still recommend peptides with Level 4-5 evidence?

Because evidence levels exist on a spectrum, not a binary. Level 4 evidence (extensive preclinical research with consistent results and strong mechanistic understanding) is meaningfully different from Level 6 (someone on Reddit said it worked). We present the evidence honestly, identify the level clearly, and let women make informed decisions. Some women decide that Level 4 evidence plus a favorable safety profile is sufficient for their situation. Others want to wait for Level 1-2 evidence. Both positions are reasonable.